Interplay between Hemostatic Pathways and Cancer Biology in Head and Neck Cancers

Malignancy and hemostatic system are interrelated. Malignancy causes thrombosis by promoting coagulation and coagulation promotes malignancy by promoting neo-angiogenesis and metastasis. A number of cancers have been implicated which show relation with hemostasis such as cancer of pancreas, lung, kidney, stomach bladder and various hematological malignancies. Head and neck squamous cell carcinomas, oral cancers and malignant gliomas are also implicated. In this article, the authors will be discussing which factor contributes to tumor progression and metastasis and which factor inhibits tumor progression.

[1]  J. Bergquist,et al.  The Eph Tyrosine Kinase Receptors EphB2 and EphA2 Are Novel Proteolytic Substrates of Tissue Factor/Coagulation Factor VIIa* , 2014, The Journal of Biological Chemistry.

[2]  C. Cho,et al.  Changes in the Laboratory Data for Cancer Patients Treated with Korean-medicine-based Inpatient Care , 2014, Journal of pharmacopuncture.

[3]  A. Falanga,et al.  Coagulation and cancer: biological and clinical aspects , 2013, Journal of thrombosis and haemostasis : JTH.

[4]  V. Seifert,et al.  Knockdown of TFPI-2 promotes migration and invasion of glioma cells , 2011, Neuroscience Letters.

[5]  C. Holmes,et al.  The platelet contribution to cancer progression , 2011, Journal of thrombosis and haemostasis : JTH.

[6]  A. Khorana,et al.  Assessing risk of venous thromboembolism in the patient with cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Lane,et al.  The haemostatic role of tissue factor pathway inhibitor. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Papavassiliou,et al.  Thrombomodulin: from haemostasis to inflammation and tumourigenesis. , 2008, The international journal of biochemistry & cell biology.

[9]  A. Buchs,et al.  Heparanase, galectin-3, and tissue factor mRNA are expressed in benign neoplasms of the thyroid , 2003, Endocrine.

[10]  W. Kisiel,et al.  Structure, function and biology of tissue factor pathway inhibitor-2 , 2005, Thrombosis and Haemostasis.

[11]  Erwin G. Van Meir,et al.  PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. , 2005, Cancer research.

[12]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.

[13]  L. Brass,et al.  Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. , 2004, Molecular cancer research : MCR.

[14]  L. Lau,et al.  Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. , 2004, Blood.

[15]  S. Patierno,et al.  Tissue factor and fibrin in tumor angiogenesis. , 2004, Seminars in thrombosis and hemostasis.

[16]  Giuseppe Cibelli,et al.  Regulation of life and death by the zinc finger transcription factor Egr‐1 , 2002, Journal of cellular physiology.

[17]  G. Thiel,et al.  Epidermal growth factor and platelet-derived growth factor induce expression of Egr-1, a zinc finger transcription factor, in human malignant glioma cells , 2001, Journal of the Neurological Sciences.

[18]  J. Matsoukas,et al.  Modulation of angiogenesis and progelatinase a by thrombin receptor mimetics and antagonists. , 2001, Endothelium : journal of endothelial cell research.

[19]  W. Kisiel,et al.  Expression of Tissue Factor and Tissue Factor Pathway Inhibitor in situ in Laryngeal Carcinoma , 1999, Thrombosis and Haemostasis.

[20]  N. Tsopanoglou,et al.  On the Mechanism of Thrombin-induced Angiogenesis , 1999, The Journal of Biological Chemistry.

[21]  Erwin G. Van Meir,et al.  Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma , 1999, Oncogene.

[22]  M. Raderer,et al.  Inhibition of metastases by anticoagulants. , 1999, Journal of the National Cancer Institute.

[23]  N. Lemoine,et al.  Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. , 1998, Cancer research.

[24]  R. Silverstein,et al.  Hypercoagulability in cancer. , 1996, Hematology/oncology clinics of North America.

[25]  N. Mackman.  Regulation of the tissue factor gene , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  B. Leone,et al.  High‐Dose Cisplatin with Dipyridamole in Advanced Non‐Small Cell Lung Cancer: A Grupo Oncologico Cooperativo del Sur Study , 1995, American journal of clinical oncology.

[27]  R. Abbate,et al.  Increased thromboxane A2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx. , 1993, Prostaglandins, leukotrienes, and essential fatty acids.

[28]  F. Meloni,et al.  Human tumor cells cultured "in vitro" activate platelet function by producing ADP or thrombin. , 1989, Haematologica.

[29]  P. Fratino,et al.  Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues. , 1989, Invasion & metastasis.

[30]  W. Henderson,et al.  Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75 , 1984, Cancer.

[31]  S. Giardina,et al.  Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. , 1982, Cancer research.